{{Infobox drug
| drug_name = 
| IUPAC_name        = 
| image             = 
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = Tretten, NovoThirteen 
| Drugs.com         = {{drugs.com|parent|tretten}}
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = C
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_NZ = <!--Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = Rx-only
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = 
| routes_of_administration = Injection
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action =
| excretion         = 
<!-- Identifiers -->
| CAS_number        = 
| ATCvet            = 
| ATC_prefix        = B02
| ATC_suffix        = BD11
| PubChem           = 
| DrugBank          = 
| ChemSpiderID      = none
| KEGG = D10532

<!-- Chemical data -->
| chemical_formula  = 
| molecular_weight  = 
}}

'''Catridecacog''' (brand name '''Tretten''' in the US and '''NovoThirteen''' in Europe<ref name=NHSnew>NHS [http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5744 New Drugs Online Report for catridecacog] Page accessed July 2, 2015</ref>) is a class of [[Recombinant DNA|recombinant]] [[factor XIII]] A-subunit based [[biopharmaceutical]] medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of [[Factor XIII deficiency]]. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. [[Food and Drug Administration]] (FDA) for this use in the US in 2014.<ref>[http://www.pharmacist.com/catridecacog-first-drug-treat-rare-genetic-blood-clotting-disorder Catridecacog: First drug to treat rare genetic blood clotting disorder].  ''The Pharmacist''  February 01, 2014
</ref>  It was brought to market by [[Novo Nordisk]].<ref name=NHSnew/>

==References==
{{reflist}}
*{{cite journal|journal=[[J Blood Med.]] |date=9 July 2014 |volume=5|pages=107–13|doi=10.2147/JBM.S35395 |title=Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency? |author=Korte W |pmid=25031548 |pmc=4096448}}
*{{cite journal|journal=[[Expert Opin Investig Drugs]] |date=July 2015 |volume=24 |issue=7 |pages=949–56 |doi=10.1517/13543784.2015.1035432 |title=Inflammatory bowel disease therapies discontinued between 2009 and 2014  |vauthors=Mozaffari S, Nikfar S, Abdollahi M  |pmid=25861835 |pmc= |quote=CNDO-210 and Catridecacog were discontinued due to safety concerns and lack of efficacy, respectively. }}

{{Antihemorrhagics}}

[[Category:Antihemorrhagics]]
[[Category:Biopharmaceuticals]]


{{blood-drug-stub}}